PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials
Article in Biomedical Research and Therapy (December 2023)
The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.
The tumor therapy landscape of synthetic lethality
Article in Nature Communications (February 2021)
BRCA Mutations and PARP Inhibitors in Breast and/or Ovarian Cancer Patients
Article in International Journal Of Pharmaceutical Research And Allied Sciences (January 2021)